Core Viewpoint - *ST Shuangcheng reported significant improvements in its financial performance for the third quarter, driven by the sales of a new product, which has positively impacted its revenue and net profit [1][2]. Financial Performance - For the first three quarters, the company achieved a revenue of 169 million yuan, representing a year-on-year increase of 33.04% [1] - The net loss attributable to shareholders was 2.52 million yuan, a substantial reduction of approximately 93.33% compared to a net loss of 37.84 million yuan in the same period last year [1] - In the third quarter alone, revenue reached 84.78 million yuan, marking a year-on-year growth of 164.39% [1] - The net profit for the third quarter was 15.94 million yuan, a turnaround from a net loss of 20.89 million yuan in the previous year [1] Cash Flow and Liabilities - The net cash flow from operating activities for the first three quarters was 32.08 million yuan, an increase of 263% year-on-year, attributed to new export product sales and reduced market development expenses [1] - The balance of contract liabilities at the end of the period increased by 31.64% compared to the beginning of the year, mainly due to milestone payments received for product sales rights in the U.S. market [1] Product Development and Market Impact - The revenue growth was primarily driven by the sales of the newly launched product, injectable paclitaxel (albumin-bound), which significantly contributed to the profit increase [1][2] - The company received FDA approval for the ANDA of injectable paclitaxel (albumin-bound) in May, which is a key factor in the substantial performance improvement in the third quarter [3] - The approval indicates that the product meets safety and efficacy standards comparable to the original research level, enhancing the company's international influence and future operational performance [3]

海南双成药业股份有限公司（以下简称"公司"）第五届董事会第二十三次 会议通知于 2025 年 10 月 27 日以书面送达或电子邮件等方式发出，并于 2025 年 10 月 29 日 10:00 以现场结合通讯表决的方式召开。会议应出席董事 6 人，实际 参加表决的董事 6 人。本次会议由董事长王成栋先生主持，会议的召开符合有关 法律法规、公司章程的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年第三季度报告的议案》 表决情况：同意 6 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过，并同意提交董事会审议。 详情请见同日刊登于《证券时报》《中国证券报》及巨潮资讯网的《海南双 成药业股份有限公司 2025 年第三季度报告》。 证券代码：002693 证券简称：*ST双成 公告编号：2025-067 海南双成药业股份有限公司 第五届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 三、备查文件 1、《海南双成药业股份有限公司第五届董事会第二十三次会议决议》。 海南双 ...

Financial Performance - The company's operating revenue for the third quarter reached ¥84,781,750.41, representing a year-on-year increase of 164.39%[3] - The net profit attributable to shareholders was ¥15,943,078.67, an increase of 176.31% compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses was ¥15,149,596.72, up 168.35% year-on-year[3] - The net profit attributable to the parent company increased by 93.33% year-on-year, driven by the sales profit from the new product[8] - The company's operating profit for the current period was -7,394,530.37, an improvement from -51,330,965.44 in the previous period, indicating a significant reduction in losses[25] - The total profit for the current period was -7,538,875.32, compared to -51,363,813.55 in the previous period, reflecting a substantial decrease in overall losses[25] - The net profit attributable to the parent company's shareholders was -2,523,479.07, a notable improvement from -37,837,689.22 in the previous period[25] Cash Flow - The net cash flow from operating activities increased by 262.79% year-to-date, totaling ¥32,081,773.07[3] - Cash inflow from operating activities totaled 191,244,462.63, compared to 151,475,766.86 in the previous period, showing a year-over-year increase[27] - Cash outflow from operating activities was 159,162,689.56, down from 171,182,964.84 in the previous period, indicating improved cash management[27] - The net cash flow from investing activities was -51,390,022.73, worsening from -16,061,574.38 in the previous period[27] - The net cash flow from financing activities was 2,614,710.40, a significant decrease from 69,322,933.39 in the previous period[27] - The ending cash and cash equivalents balance was 28,699,487.14, down from 37,070,882.11 in the previous period, reflecting a decline in liquidity[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥797,770,471.93, a 1.77% increase from the end of the previous year[3] - The company's total assets increased to ¥797,770,471.93 from ¥783,866,026.52, reflecting a growth of 1.15%[22] - Total liabilities rose to ¥393,424,894.74 from ¥372,260,377.26, marking an increase of 5.1%[22] - The total equity attributable to shareholders decreased to ¥390,893,020.73 from ¥393,409,970.88, a decline of 0.4%[22] - Cash and cash equivalents decreased to ¥28,699,487.14 from ¥45,105,842.30, a drop of 36.2%[20] - Inventory increased to ¥85,659,863.26 from ¥80,535,394.02, an increase of 6.6%[20] - The company’s investment properties decreased to ¥15,493,180.48 from ¥17,597,890.39, a decline of 11.97%[20] Operating Costs and Expenses - The company reported a 33.04% increase in total operating income year-on-year, primarily due to the sales of the newly listed product, paclitaxel injection (albumin-bound)[7] - The cost of goods sold increased by 43.79% year-on-year, attributed to the higher production costs of the new product[7] - Research and development expenses decreased by 39.76% year-on-year, reflecting reduced investment in research activities[8] - Research and development expenses decreased to ¥6,040,736.81 from ¥10,028,401.53, a reduction of 39.6%[24] - Total operating costs decreased slightly to ¥180,108,046.32 from ¥180,496,024.50, with operating costs specifically rising to ¥73,115,398.25 from ¥50,847,128.40, indicating a significant increase of 43.8%[24] - The company experienced a 391.31% increase in non-operating expenses year-on-year, mainly due to increased losses from fixed asset disposals[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,166[12] - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., holds 32.92% of the shares, totaling 136,516,546 shares[12] Investment Activities - Investment cash inflows decreased by 55.19% compared to the same period last year, primarily due to a reduction in the recovery of financial investments[10] - Cash paid for investments decreased by 46.30% year-on-year, mainly due to a reduction in financial investments during the reporting period[10] - Net cash flow from investment activities decreased by 219.96% compared to the same period last year, primarily due to a decrease in net cash flow from financial investments[10] - Cash received from investment increased by 262.67% year-on-year, mainly due to an increase in stock subscription payments during the reporting period[10] Audit Status - The company has not undergone an audit for the third quarter financial report[29]

Core Viewpoint - The company has obtained a revised "Drug Production License" from the Hainan Provincial Drug Administration, allowing it to continue contract manufacturing for two specific drugs, which is expected to enhance production capacity and maintain stable operations without significant short-term impact on performance [1][2]. Group 1: License Details - The license change involves the continuation of contract manufacturing for the injectable drugs Aibowetai and Bivalirudin, with a contract validity of three years from the approval date [1][2]. - The production facilities are located at No. 16, Xingguo Road, Xiuying District, Haikou City, specifically in the freeze-dried powder injection workshop [1][2]. Group 2: Company Information - The company is registered at No. 16, Xingguo Road, Xiuying District, Haikou City, with a social credit code of 9146000072122491XG [1]. - The legal representative is Wang Chengdong, and the quality responsible person is Li Yuan [1]. Group 3: Production Capacity and Market Demand - The license renewal is expected to improve the company's capacity utilization and optimize production structure, thereby meeting market demand [2]. - The short-term impact on the company's performance is not expected to be significant [2].

企业名称：海南双成药业股份有限公司 注册地址：海口市秀英区兴国路 16 号 证券代码：002693 证券简称：*ST双成 公告编号：2025-066 海南双成药业股份有限公司 关于公司药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 海南双成药业股份有限公司（以下简称"公司"）于近日取得海南省药品监 督管理局颁发变更后的《药品生产许可证》。本次主要涉及变更的事项为：同意 公司延续接受前沿生物药业（南京）股份有限公司委托生产注射用艾博韦泰（国 药准字 H20180006），生产地址及车间、生产线为海口市秀英区兴国路 16 号冻干 粉针剂三车间、冻干粉针剂生产线，委托有效期自批准之日起三年；同意公司延 续接受苏州二叶制药有限公司委托生产注射用比伐芦定（国药准字 H20193019）； 生产地址及车间生产线为海口市秀英区兴国路 16 号冻干粉针剂三车间、冻干粉 针剂生产线；委托有效期自批准之日起三年。其他内容不变。现将相关情况公告 如下： 社会信用代码：9146000072122491XG 法定代表人：王成栋 企业负责人：LI JIANMIN ...

Group 1 - The Hainan Free Trade Zone concept rose by 2.58%, ranking first among concept sectors, with 22 stocks increasing, including Haixia Co., Haima Automobile, and ST Huawen hitting the daily limit [1][2] - Notable gainers included Haikou Group, Hainan Haiyao, and Kangzhi Pharmaceutical, which rose by 6.38%, 6.14%, and 5.69% respectively [1] - The stocks with the largest declines were Hainan Huatie, Junda Co., and *ST Shuangcheng, which fell by 1.30%, 1.23%, and 1.06% respectively [1] Group 2 - The Hainan Free Trade Zone concept saw a net inflow of 358 million yuan from main funds, with 18 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan [2] - The top net inflow stock was Haixia Co., with a net inflow of 108 million yuan, followed by HNA Holding, Hainan Development, and Haide Co. with net inflows of 89.09 million yuan, 82.73 million yuan, and 64.19 million yuan respectively [2][3] - The highest net inflow ratios were seen in Haide Co., ST Huawen, and Hainan Haiyao, with ratios of 14.30%, 13.37%, and 12.49% respectively [3] Group 3 - The top stocks in the Hainan Free Trade Zone concept included Haixia Co. with a daily increase of 10.03% and a turnover rate of 6.55%, followed by HNA Holding with a 1.80% increase and a turnover rate of 2.30% [3][4] - Other notable performers included Hainan Development with a 2.99% increase and a turnover rate of 8.46%, and Haikou Group with a 6.38% increase and a turnover rate of 7.54% [4] - Stocks such as Hainan Huatie and Junda Co. experienced declines of 1.30% and 1.23% respectively, with negative main fund flows [4]

Core Viewpoint - The company is preparing for the production of injectable bortezomib, which has not yet been officially launched in the market [1] Group 1: Company Response - The company addressed investor concerns regarding the impact of the original drug (bortezomib) from Johnson & Johnson/Takeda on its operations [1] - The company indicated that injectable bortezomib is currently in the pre-production stage [1] Group 2: Market Position - The company was asked about the market share of other generic drug companies in the local market [1] - The company provided no specific details on its market share in the Australian market [1]

Core Points - The company has received marketing authorization for injectable bortezomib from the Australian Therapeutic Goods Administration (TGA) [1][4] - The product is indicated for multiple myeloma and mantle cell lymphoma treatment in specific patient populations [2][3] Drug Information - Product Name: Injectable Bortezomib - Dosage Form: Injection - Specification: 3.5 mg - Approved Indications: - Treatment of previously untreated multiple myeloma patients who are not suitable for high-dose chemotherapy, in combination with melphalan and prednisone [1] - Part of combination therapy for previously untreated multiple myeloma patients under 65 years old, for high-dose chemotherapy with autologous stem cell rescue [1] - Treatment for multiple myeloma patients who have received at least one prior therapy and have disease progression [2] - Treatment for adult patients with previously untreated mantle cell lymphoma in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [2] Impact on the Company - The approval signifies the product's eligibility for sale in Australia, positively impacting the company's overseas market expansion and performance [4] - The export business may face uncertainties due to market demand fluctuations, policy changes, exchange rate volatility, and market competition [4]

Core Viewpoint - *ST Shuangcheng has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product portfolio and potential market opportunities in treating multiple myeloma and mantle cell lymphoma patients [1] Summary by Categories Product Approval - The company has obtained a marketing license for injectable bortezomib from the TGA [1] - The approved indications include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy, as well as those who have received at least one prior treatment and have disease progression [1] Treatment Combinations - Bortezomib is approved for use in combination with melphalan and prednisone for treating previously untreated multiple myeloma patients [1] - It is also indicated for use in conjunction with high-dose chemotherapy and autologous stem cell rescue for patients under 65 years old who have not received prior treatment [1] - Additionally, it is approved for use with rituximab, cyclophosphamide, doxorubicin, and prednisone for treating adult patients with previously untreated mantle cell lymphoma [1]

Core Viewpoint - *ST Shuangcheng (002693.SZ) has received marketing approval from the Australian Therapeutic Goods Administration (TGA) for injectable bortezomib, indicating a significant advancement in its product offerings for treating multiple myeloma and mantle cell lymphoma patients [1] Group 1: Product Approval Details - The approved indications for bortezomib include treatment for previously untreated multiple myeloma patients who are unsuitable for high-dose chemotherapy when used in combination with melphalan and prednisone [1] - It is also approved for use in patients under 65 years old with previously untreated multiple myeloma as part of a high-dose chemotherapy regimen combined with autologous stem cell rescue following prior induction therapy [1] - The drug is indicated for patients who have received at least one prior treatment and whose disease has progressed [1] - Additionally, it is approved for adult patients with previously untreated mantle cell lymphoma when used in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone [1]